All In Biotech

Drug Trial Radar · NCT00369837

Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

Evaluation of the Effect of Ultrashort-Acting Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

Last checked: Nov 20, 2026Latest source record: May 22, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Sep 2006

Primary completion

Jan 2007

Study completion Feb 2007

Sponsor

Lead sponsor
The Medicines CompanyIndustry
Sponsor type
Industry
First posted
Aug 29, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the safety of clevidipine for treating severely elevated blood pressure, defined as systolic (SBP) \>180 mmHg and/or diastolic blood pressure (DBP) \>115 mmHg assessed on 2 successive occasions 15 minutes apart at baseline, in patients with or without major organ injury, particularly with respect to controlled dose adjustment to desired effect and prolonged continuous infusion. Enrollment of patients into the study was to continue until the target goal of 100 patients with at least 18 hours of continuous clevidipine treatment, including a minimum of 50 patients with acute or chronic end-organ injury, was met.

Conditions

  • Hypertension

Interventions

  • clevidipineDrug

    Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients in whom SBP falls below the lower limit of the patient-specific, pre-determined blood pressure target range at the initial dose (2.0 mg/h)Time frame: Study drug initiation through the first 3 minutes of the infusion
  2. Percentage of patients who reach the prespecified target SBP rangeTime frame: Within 30 minutes of the initiation of the infusion

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Jackson Hospital

    Montgomery, Alabama

  • VA Medical Center W. LA

    Los Angeles, California

  • The George Washington University Medical Center

    Washington D.C., District of Columbia

  • Louisiana State University Medical Center/Charity Hospital

    New Orleans, Louisiana

  • Critical Care Research Center at Louisiana State University Health Sciences Center

    Shreveport, Louisiana

  • Good Samaritan Hospital

    Baltimore, Maryland

  • Duke University Medical Center

    Durham, North Carolina

  • Metrohealth Medical Center

    Cleveland, Ohio

  • The Cleveland Clinic

    Cleveland, Ohio

  • The Toledo Hospital

    Toledo, Ohio

  • Providence Heart & Vascular Institute, d/b/a Providence St. Vincent Medical Center

    Portland, Oregon

  • Hamot Shock Trauma

    Erie, Pennsylvania

  • Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • The University of Texas Health Science Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.